

IFW

PATENT
ATTORNEY DOCKET NO.: 056291-5184

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

Anderson J. RYAN

Application No.: 10/511,744

Group Art Unit: 1646

Filed: October 18, 2004

Examiñer: Unassigned

**FOR: COMBINATION THERAPY FOR THE
TREATMENT OF CANCER**

Date: July 28, 2005

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, **Mail Stop** _____
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:


INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Citation of Related U.S. Patent Applications

The Examiner's attention is directed to the following related co-pending U.S. patent applications:

<u>Examiner's Initials</u>	<u>Inventor</u>	<u>U.S. Serial No.</u> <u>Filing Date</u>	<u>U.S. Patent No.</u> <u>Issue Date</u>	<u>PCT Publ. No.</u> <u>Date</u>
<i>ark</i>	Davis et al.	09/890,989		00/48591 Aug. 24, 2000
<i>ark</i>	Thomas et al.	10/129,336 May 3, 2002		01/32651 May 10, 2001
<i>ark</i>	Curwen et al.	10/240,413 October 1, 2002		01/74360 October 11, 2001
<i>ark</i>	Davis et al.	10/240,213 April 4, 2003	6,906,048 June 14, 2005	01/74368 October 11, 2001

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
Patent and Trademark Office



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket No.	Client Ref.
056291-5184	
Applicant: Anderson J. Ryan	
Appln. No.: 10/511,744	
Filing Date: October 18, 2004	
Examiner: Unassigned	Group Art Unit: 1646

Date: July 28, 2005

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
Arh	6,423,753 B1	07/2002	Dougherty			
Arh	1. 5,770,599	06/1998	Gibson			
Arh	2. 5,616,582	04/1997	Barker			
Arh	3. 5,457,105	10/1995	Barker			
Arh	4. 2003-0144298 A1	07/2003	Curwen et al.			
Arh	5. 2003-0166617 A1	09/2003	Davis et al.			

FOREIGN PATENT DOCUMENTS


	Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclosed	No
Arh	6. 96/33980	031/1996	WO	Gibson (equivalent to US 6,770,599)				
Arh	7. 99/02166	01/1999	WO	Dougherty (equivalent to US 6,423,753)				
Arh	8. 00/48591	08/2000	WO	Davis et al.				
Arh	9. 01/32651 A1	05/2001	WO	Hennequin et al.				
Arh	10. 01/74360 A1	10/2001	WO	Curwen et al.				
Arh	11. 01/74368 A1	10/2001	WO	Davis et al.				
Arh	12. 02/056692 A1	07/2002	WO	Lee et al.				

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Arh	13.	Baker et al., "Blockade of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling for Therapy of Metastatic Human Pancreatic Cancer", Cancer Research, 62, April 2002, pp. 1996-2003				
Arh	14.	Blakey et al., "Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models", Clinical Cancer Research, vol. 8, 2002, pp. 1974-1983				
Arh	15.	Bruns et al., "Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in a nude mouse model", European Journal of Cancer, vol. 38, Suppl. 7, November 2, p. 40				
Arh	16.	Chaplin et al., "The Development of Combretastatin A4 Phosphate as a Vascular Targeting Agent", Int. J. Radiation Oncology Biol. Phys. vol. 54, no. 5, 2002, pp. 1491-1496				
Arh	17.	Ciadiello et al., "Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor", Clinical Cancer Research, vol. 6, May 2000, pp. 2053-2063				

Examiner: <i>Erica Hughes</i>	Date Considered: <i>03/16/2007</i>
*EXAMINER Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
Patent and Trademark Office



**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Docket No.	Client Ref.
056291-5184	
Applicant: Anderson J. Ryan	
Appln. No.: 10/511,744	
Filing Date: October 18, 2004	
Examiner: Unassigned	Group Art Unit: 1646

Date: July 28, 2005

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
<i>an</i>	6,906,048	06/2005	Davis et al.			

FOREIGN PATENT DOCUMENTS

ORIGINAL PAPER DOCUMENTS						Abstract		Readily Available	
		Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	Enclosed	No	Enclosed	No

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

<i>an</i>	18.	Ciardiello et al., "Antiangiogenic and Antitumor Activity of Anti-Epidermal Growth Factor Receptor C225 Monoclonal Antibody in Combination with Vascular Endothelial Growth Factor Antisense Oligonucleotide of Human GEO Colon Cancer Cells", Clinical Cancer Research, vol. 6, September 2000, pp. 3739-3747				
<i>an</i>	19.	Ciardiello et al., "A Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor Receptor", Clinical Cancer Research, vol. 7, no. 10, October 2001, pp. 2958-2970				
<i>an</i>	20.	Davis et al., "ZD6126: A Novel Vascular-targeting Agent That Causes Selective Destruction of Tumor Vasculature", Cancer Research, 62, December 2002, pp. 7247-7253				
<i>an</i>	21.	Grosios et al., "Combination Chemotherapy with Combretastatin A-4 Phosphate and 5-Fluorouracil in an Experimental Murine Colon Adenocarcinoma", Anticancer Research, 20, 2000, pp. 229-234				
<i>an</i>	22.	Horsman et al., "Combretastatins Novel Vascular Targeting Drugs for Improving the Anti-Cancer Therapy", Adv. Exp. Med. Biol. 2000, 476, pp. 311-323				
<i>an</i>	23.	Huang et al., "Modulation of Radiation Response and Tumor-induced Angiogenesis after Epidermal Growth Factor Receptor Inhibition by ZD1839 (Iressa)", Cancer Research, 62, August 2002, pp. 4300-4306				

Examiner: <i>[Signature]</i>	Date Considered: 03/16/2007
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
Patent and Trademark Office



Attorney Docket No.	Client Ref.
056291-5184	
Applicant: Anderson J. Ryan	
Appln. No.: 10/511,744	
Filing Date: October 18, 2004	
Examiner: Unassigned	Group Art Unit: 1646

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Date: July 28, 2005

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	Abstract		Readily Available	
						Enclosed	No	Enclosed	No

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

ark	24.	Li et al., "Preclinical Evaluations of Therapies Combining the Vascular Targeting Agent Compretastatin A-4 Disodium Phosphate and Conventional Anticancer Therapies in the Treatment of Kaposi's Sarcoma", Acta Oncologica, 41, 2002, pp. 91-97				
ark	25.	Raben et al., "ZD1839, a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Alone and in Combination With Radiation and Chemotherapy as a New Therapeutic Strategy in Non-Small Cell Lung Cancer", Seminars in Oncology, vol. 29, no. 1, Suppl 4, February 2000, pp. 37-46				
ark	26.	Siemann et al., "Vascular Targeting Agents Enhance Chemotherapeutic Agent Activities in Solid Tumor Therapy", Int. j. Cancer, 99, 2002, pp. 1-6				
ark	27.	Siemann et al., "Enhancement of Radiation Therapy by the Novel Vascular Targeting Agent ZD6126", Int. J. Radiation Oncology Bio. Phys., vol. 53, no. 1, 2002, pp. 164-171				
ark	28.	Sirotnak et al., "Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced by Coadministration of ZD1839 (Iressa), and Inhibitor of EGFR Tyrosine Kinase", Clinical Cancer Research, vol. 6, December 2000, pp. 4885-4892				
ark	29.	Thorpe et al., The First International Conference on Vascular Targeting: Meeting Overview", Cancer Research, 63, March 2003, pp. 1144-1147				
ark	30.	Viloria-Petit et al., "Acquired Resistance to the Antitumor Effect of Epidermal Growth Factor Receptor-blocking Antibodies <i>in Vivo</i> : A Role for Altered Tumor Angiogenesis", Cancer Research, 61, July 2001, pp. 5090-5101				

Examiner: *[Signature]* Date Considered: 03/16/2007

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 056291-5184		Client Ref. 10/511742 100697-1P US				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Joseph Anderson RYAN						
		Appl. No.: To Be Assigned						
		Filing Date: Concurrently						
		Examiner: Unassigned		Group Art Unit: Unassigned				
Date: October 18, 2004		Page 1 of 1						
U.S. PATENT DOCUMENTS								
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)		
AR								
BR								
CR								
DR								
ER								
FR								
FOREIGN PATENT DOCUMENTS								
	Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclosed	No
GR	99/02166 A	01/1999	WIPO	Dougherty				
HR	96/33980 A	031/1996	WIPO	Gibson				
IR								
JR								
KR								
LR								
MR								
NR								
OR								
PR								
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)								
QR	Ciardiello et al., "A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor", Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol. 7, no. 10, October 2001, pp. 2958-2970, XP002248479, ISSN: 1078-0432							
RR								
SR								
TR								
UR								
VR								
WR								
XR								
Examiner		Date Considered: 03/17/2006						
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.								